Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2026)

Collegium Pharmaceutical's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $8.9 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 10.56% year-over-year to $8.9 million in Q1 2026; TTM through Mar 2026 was $8.9 million, a 10.56% decrease from a year earlier, with the FY2025 full-year figure at $9.1 million, down 8.89% from the prior year.
• Non-Current Deffered Revenue eased to $8.9 million in Q1 2026 per COLL's latest filing, from $9.1 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $10.0 million in Q3 2024 and bottomed at $8.9 million in Q1 2026.
• The 3-year median for Non-Current Deffered Revenue is $10.0 million (2024), against an average of $9.6 million.
• Across the five-year window, Non-Current Deffered Revenue slipped 7.22% in 2025 and retreated 10.56% in 2026, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $10.0 million in 2024, then fell by 8.89% to $9.1 million in 2025, then fell by 1.83% to $8.9 million in 2026.
• Per Business Quant, the three latest COLL Non-Current Deffered Revenue figures stand at $8.9 million (Q1 2026), $9.1 million (Q4 2025), and $9.3 million (Q3 2025).